Biotech companies used to think about how to build enduring companies with soup-to-nuts operations that had everything under one corporate flag, from research to development to manufacturing to marketing. Those models increasingly look like relics. Investors have grown weary of the long timelines, big bucks, and high risk that comes with building such organizations. Stung by losses, a number of VCs, entrepreneurs and investors are turning to small core teams that lean heavily on contract firms to try to make biotech more nimble, less capital intensive, and a more attractive industry for investment. Come join Xconomy for a number of case studies and interactive chats with national leaders who are looking to reinvent the biotech business model.
Confirmed Speakers
- Corey Goodman
- Partner, venBio
- John Maraganore
- CEO, Alnylam Pharmaceuticals
- Kevin Starr
- Partner, Third Rock Ventures
- Kathy Glaub
- President, Plexxikon
- Carl Weissman
- CEO, Accelerator
- Thong Le
- Managing Director, WRF Capital
- Carol Gallagher
- former CEO, Calistoga Pharmaceuticals
- Bruce Montgomery
- CEO, Cardeas Pharma
- Heather Franklin
- CEO, Blaze Bioscience
- Peppi Prasit
- Founder, Inception Sciences
- David McElligott
- CSO, Groove Biopharma
- Steve Tregay
- CEO, Forma Therapeutics
- Brian Atwood
- Managing Director, Versant Ventures
- Alex Lash
- Biopharma editor, Start-Up, In Vivo
- Ed Saltzman
- President, Defined Health
Schedule
Registration: 1:00 – 2:00 pm
Program: 2:00 – 6:00 pm
Networking Reception: 6:00 – 7:00 pm
Registration Information
Super Saver Rate (ends Feb. 1) $125
Startup Special $95 (for employees of startups less than 3 years old with 20 or fewer employees)
Regular Registration $195
Student Registration $30
Walk-in Registration $275
